China National Medicines Corp Ltd (SHG:600511) — Market Cap & Net Worth
Market Cap & Net Worth: China National Medicines Corp Ltd (600511)
China National Medicines Corp Ltd (SHG:600511) has a market capitalization of $3.16 Billion (CN¥21.62 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #4776 globally and #884 in its home market, demonstrating a 0.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China National Medicines Corp Ltd's stock price CN¥28.66 by its total outstanding shares 754502998 (754.50 Million). Analyse China National Medicines Corp Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
China National Medicines Corp Ltd Market Cap History: 2015 to 2026
China National Medicines Corp Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.71 Billion to $3.16 Billion (-0.42% CAGR).
China National Medicines Corp Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China National Medicines Corp Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.07x
China National Medicines Corp Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.89x
China National Medicines Corp Ltd's market cap is 1.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.71 Billion | $12.08 Billion | $512.85 Million | 0.31x | 7.23x |
| 2016 | $2.95 Billion | $34.61 Billion | $990.19 Million | 0.09x | 2.98x |
| 2017 | $2.74 Billion | $36.28 Billion | $1.14 Billion | 0.08x | 2.40x |
| 2018 | $2.33 Billion | $38.74 Billion | $1.40 Billion | 0.06x | 1.66x |
| 2019 | $2.79 Billion | $44.64 Billion | $1.60 Billion | 0.06x | 1.74x |
| 2020 | $5.12 Billion | $40.38 Billion | $1.38 Billion | 0.13x | 3.70x |
| 2021 | $3.32 Billion | $46.47 Billion | $1.75 Billion | 0.07x | 1.90x |
| 2022 | $3.02 Billion | $45.50 Billion | $1.96 Billion | 0.07x | 1.54x |
| 2023 | $3.16 Billion | $49.70 Billion | $2.15 Billion | 0.06x | 1.47x |
| 2024 | $3.78 Billion | $50.60 Billion | $2.00 Billion | 0.07x | 1.89x |
Competitor Companies of 600511 by Market Capitalization
Companies near China National Medicines Corp Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to China National Medicines Corp Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #246 globally with a market cap of $99.71 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #441 globally with a market cap of $59.14 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #570 globally with a market cap of $45.94 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1111 globally with a market cap of $22.95 Billion USD ( AU$32.44 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #246 | McKesson Corporation | NYSE:MCK | $99.71 Billion | $814.02 |
| #441 | Cencora Inc. | NYSE:COR | $59.14 Billion | $304.00 |
| #570 | Cardinal Health Inc | NYSE:CAH | $45.94 Billion | $195.24 |
| #1111 | Sigma Healthcare Ltd | AU:SIG | $22.95 Billion | AU$2.81 |
China National Medicines Corp Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, China National Medicines Corp Ltd's market cap moved from $3.71 Billion to $ 3.16 Billion, with a yearly change of -0.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.16 Billion | -0.31% |
| 2025 | CN¥3.17 Billion | -15.98% |
| 2024 | CN¥3.78 Billion | +19.57% |
| 2023 | CN¥3.16 Billion | +4.72% |
| 2022 | CN¥3.02 Billion | -9.24% |
| 2021 | CN¥3.32 Billion | -35.00% |
| 2020 | CN¥5.12 Billion | +83.60% |
| 2019 | CN¥2.79 Billion | +19.48% |
| 2018 | CN¥2.33 Billion | -15.03% |
| 2017 | CN¥2.74 Billion | -7.11% |
| 2016 | CN¥2.95 Billion | -20.33% |
| 2015 | CN¥3.71 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of China National Medicines Corp Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.16 Billion USD |
| MoneyControl | $3.16 Billion USD |
| MarketWatch | $3.16 Billion USD |
| marketcap.company | $3.16 Billion USD |
| Reuters | $3.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About China National Medicines Corp Ltd
China National Medicines Corporation Ltd., together with its subsidiaries, engages in pharmaceutical equipment circulation in China. The company also manufactures and sells new drugs; sells Chinese patent medicines drug sales and western medicines, and medical equipment; and offers dental academic services, warehousing, logistics and import and export agency services. It also serves hospitals, re… Read more